---
title: CTAD Conference Schedule Highlights
description: The Clinical Trials on Alzheimer's Disease (CTAD) conference kicks off in San Francisco this week and ATRI leadership are involved w/ many of the sessions.
---

[USC Epstein Family Alzheimer’s Therapeutic Research Institute - News & Events](https://atrinews.usc.edu)

# [CTAD Conference Schedule Highlights](https://atrinews.usc.edu/atri-at-ctad-2022)

 Written by [ATRI](https://atrinews.usc.edu/author/atri) | Nov 30, 2022 4:55:11 PM

The Clinical Trials on Alzheimer's Disease ([CTAD](https://www.ctad-alzheimer.com/)) conference kicks off in San Francisco this week and ATRI leadership, along with our fellow Alzheimer's Clinical Trials Consortium ([ACTC](https://www.actcinfo.org/)) members, are involved with many of the sessions. The sessions will provide insight into some of the work being done by ACTC members and collaborators.

Below you'll find a list of key sessions the ATRI leadership helped make possible. ATRI's Dr. Paul Aisen will also be giving the introduction at the opening ceremony. 

Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer’s Disease Clinical Trial Recruitment through Centralized Pre-screening   
— Includes [Paul Aisen](https://atri.usc.edu/faculty/paul-aisen/), [Rema Raman](https://atri.usc.edu/faculty/rema-raman/), and [Gustavo Jimenez-Maggiora](https://atri.usc.edu/faculty/gustavo-jimenez-maggiora/). 

Long-Term Nicotine Treatment of Mild Cognitive Impairment (The MIND Study): Baseline Characteristics and Study Progress   
— Includes Paul Aisen and Rema Raman.

The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer's Disease Trials   
— Includes Paul Aisen, Rema Raman, [Michael Donohue](https://atri.usc.edu/faculty/mike-donohue/), [Robert Rissman](https://atri.usc.edu/faculty/robert-rissman/) and Gustavo Jimenez-Maggiora. 

Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer’s Disease   
— Includes Paul Aisen, Rema Raman, Michael Donohue and Robert Rissman.

Impact of Alzheimer’s Disease Biomarker Disclosure to Cognitively Unimpaired Individuals: Experiences from a Truncated Randomized Phase 2b/3 Clinical Trial   
— Includes Paul Aisen, Rema Raman and Michael Donohue.

**Assessing Clinically Meaningful Functional Outcomes in Preclinical Alzheimer’s Disease**   
— Includes Paul Aisen, Rema Raman and Michael Donohue.

Disease Progression Modelling Identified MRI-based Subtypes with Cognitive Heterogeneity in A4 Study Preclinical Trial Cohort   
— Includes Michael Donohue.

To see the entire CTAD conference schedule [click here](https://www.ctad-alzheimer.com/final-program).

[View full post](https://atrinews.usc.edu/atri-at-ctad-2022)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "ATRI"
  },
  "dateModified" : "2023-06-20T23:01:53.004Z",
  "datePublished" : "2022-11-30T16:55:11Z",
  "headline" : "CTAD Conference Schedule Highlights",
  "image" : {
    "@type" : "ImageObject",
    "height" : 658,
    "url" : "https://21078696.fs1.hubspotusercontent-na1.net/hubfs/21078696/Screenshot%202022-11-28%20at%203.26.22%20PM.png",
    "width" : 1010
  },
  "mainEntityOfPage" : "https://atrinews.usc.edu/atri-at-ctad-2022",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News & Events"
  }
}
```